Biorestorative Therapies (BRTX) Stock
Small biotech company developing regenerative medicine treatments. Here's the price, business snapshot, and what's worth knowing about Biorestorative Therapies in October 2026.
BioRestorative Therapies Inc (BRTX) is a microcap company operating in the regenerative medicine / biotechnology space. With a market capitalisation of about $13.8m, it is small and typically considered speculative. Investors should know the business may be development‑stage with limited or variable revenue, and value drivers tend to be clinical progress, regulatory milestones and partnerships rather than steady earnings. Shares can be illiquid and subject to wide price swings; there is a material risk of dilution if the company raises capital. Time horizons for drug or device development are long and outcomes uncertain, so potential upside comes with significant downside risk. This summary is for general educational purposes only and not personalised investment advice — consider your risk tolerance, conduct further research and, if needed, consult a financial adviser before making decisions.
Biorestorative Therapies (BRTX) Stock Forecast
Analyst price target, next 12 months
$160.00
+7376.6% vs today's $2.14
Price range over the last 12 months
Close to its 12-month low
Analysts covering Biorestorative Therapies have a consensus 12-month target of $160.00, above the current price of $2.14.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying BioRestorative Therapies' stock with a target price of $160, indicating significant growth potential.
Financial Health
Biorestorative Therapies Inc. shows strong revenue and cash flow, indicating healthy financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Regenerative focus
The company works in regenerative medicine where clinical milestones can drive value — though outcomes and timelines are uncertain.
Microcap volatility
With a market cap around $13.8m, shares may be illiquid and prone to large swings; expect higher risk and potential dilution.
Clinical and funding timing
Progress often depends on trials, approvals and partnerships, meaning cash needs and long timelines; performance can vary considerably.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
